American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary Cirrhosis

被引：98

作者：

Silveira, Marina G. ^{[2
]}

Brunt, Elizabeth M. ^{[3
]}

Heathcote, Jenny ^{[4
]}

Gores, Gregory J. ^{[2
]}

Lindor, Keith D. ^{[2
]}

Mayo, Marlyn J. ^{[1
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA

[2] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA

[3] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA

[4] Univ Toronto, Div Gastroenterol, Toronto, ON, Canada

来源：

HEPATOLOGY | 2010年 / 52卷 / 01期

关键词：

QUALITY-OF-LIFE; URSODEOXYCHOLIC ACID THERAPY; MAYO RISK SCORE; NATURAL-HISTORY; BIOCHEMICAL RESPONSE; TREATED PATIENTS; SERUM BILIRUBIN; PROGNOSTIC IMPORTANCE; HISTOLOGIC FEATURES; PORTAL-HYPERTENSION;

D O I：

10.1002/hep.23637

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

引用

页码：349 / 359

页数：11

共 80 条

[1]

International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].

Alvarez, E ;

Berg, PA ;

Bianchi, FB ;

Bianchi, L ;

Burroughs, AK ;

Cancado, EL ;

Chapman, RW ;

Cooksley, WGE ;

Czaja, AJ ;

Desmet, VJ ;

Donaldson, RT ;

Eddleston, ALWF ;

Fainboim, L ;

Heathcote, J ;

Homberg, JC ;

Hoofnagle, JH ;

Kakumu, S ;

Krawitt, EL ;

Mackay, IR ;

MacSween, RNM ;

Maddrey, WC ;

Manns, MP ;

McFarlane, IG ;

zum Büschenfelde, KHM ;

Mieli-Vergani, G ;

Nakanuma, Y ;

Nishioka, M ;

Penner, E ;

Porta, G ;

Portmann, BC ;

Reed, WD ;

Rodes, J ;

Schalm, SW ;

Scheuer, PJ ;

Schrumpf, E ;

Seki, T ;

Toda, G ;

Tsuji, T ;

Tygstrup, N ;

Vergani, D ;

Zeniya, M .

JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938

[2]

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid [J].

Angulo, P ;

Lindor, KD ;

Therneau, TM ;

Jorgensen, RA ;

Malinchoc, M ;

Kamath, PS ;

Dickson, ER .

LIVER, 1999, 19 (02) :115-121

[3]

Statins in liver disease: A molehill, an iceberg, or neither? [J].

Argo, Curtis K. ;

Loria, Paola ;

Caldwell, Stephen H. ;

Lonardo, Amedeo .

HEPATOLOGY, 2008, 48 (02) :662-669

[4]

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis [J].

Bonnand, AM ;

Heathcote, EJ ;

Lindor, KD ;

Poupon, RE .

HEPATOLOGY, 1999, 29 (01) :39-43

[5]

Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease [J].

Brunt, EM ;

Ramrakhiani, S ;

Cordes, BG ;

Neuschwander-Tetri, BA ;

Janney, CG ;

Bacon, BR ;

Di Bisceglie, AM .

MODERN PATHOLOGY, 2003, 16 (01) :49-56

[6]

Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis [J].

Canbay, A ;

Higuchi, H ;

Bronk, SF ;

Taniai, M ;

Sebo, TJ ;

Gores, GJ .

GASTROENTEROLOGY, 2002, 123 (04) :1323-1330

[7]

Fatigue in primary biliary cirrhosis [J].

Cauch-Dudek, K ;

Abbey, S ;

Stewart, DE ;

Heathcote, EJ .

GUT, 1998, 43 (05) :705-710

[8]

BENEFICIAL EFFECT OF AZATHIOPRINE AND PREDICTION OF PROGNOSIS IN PRIMARY BILIARY-CIRRHOSIS - FINAL RESULTS OF AN INTERNATIONAL TRIAL [J].

CHRISTENSEN, E ;

NEUBERGER, J ;

CROWE, J ;

ALTMAN, DG ;

POPPER, H ;

PORTMANN, B ;

DONIACH, D ;

RANEK, L ;

TYGSTRUP, N ;

WILLIAMS, R .

GASTROENTEROLOGY, 1985, 89 (05) :1084-1091

[9]

COLINA F, 1992, GASTROENTEROLOGY, V102, P1319

[10]

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis [J].

Combes, B ;

Emerson, SS ;

Flye, NL ;

Munoz, SJ ;

Luketic, VA ;

Mayo, MJ ;

McCashland, TM ;

Zetterman, RK ;

Peters, MG ;

Di Bisceglie, AM ;

Benner, KG ;

Kowdley, KV ;

Carithers, RL ;

Rosoff, L ;

Garcia-Tsao, G ;

Boyer, JL ;

Boyer, TD ;

Martinez, EJ ;

Bass, NM ;

Lake, JR ;

Barnes, DS ;

Bonacini, M ;

Lindsay, KL ;

Mills, AS ;

Markin, RS ;

Rubin, R ;

West, AB ;

Wheeler, DE ;

Contos, MJ ;

Hofmann, AF .

HEPATOLOGY, 2005, 42 (05) :1184-1193

← 1 2 3 4 5 6 7 8 →